Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Analyst Downgrade Sends Shockwaves Through Apple’s Investor Base

Robert Sasse by Robert Sasse
October 4, 2025
in Analysis, Nasdaq, Tech & Software
0
Apple Stock
0
SHARES
14
VIEWS
Share on FacebookShare on Twitter

A surprising analyst move has placed Apple under significant scrutiny, though the pressure stems from an unexpected source. Rather than reacting to disappointing earnings or sluggish sales figures, the market is digesting a severe rating cut from financial firm Jefferies. The institution has downgraded Apple’s stock to “Underperform,” setting a price target of $205. This projection implies a potential 20% decline from current levels.

The Foldable iPhone Debate Intensifies

The core of Jefferies’ pessimistic assessment revolves around the highly anticipated foldable iPhone. According to the firm’s analysis, Wall Street’s enthusiasm for this upcoming device is misplaced. Analyst Edison Lee issued a stark warning, suggesting that expectations for the so-called iPhone 18 Fold are dramatically overinflated. While market participants are betting on a revolutionary clamshell device, Jefferies estimates annual sales potential at a modest 3 million units.

Several key concerns underpin this cautious outlook:
* Excessively optimistic market forecasts for the iPhone 18 Fold
* Inherently limited market potential for foldable devices as a category
* Unsustainability of price-driven upgrade cycles
* Mounting pressure on profit margins in the absence of genuine innovation

Should investors sell immediately? Or is it worth buying Apple?

A particularly contentious point raised is that the market success of the iPhone 17 has artificially inflated expectations for the foldable model to unrealistic heights. Jefferies highlights the significant risk that Apple may fail to meet these elevated hopes.

A Contrarian Stance in a Divided Market

The stance taken by Jefferies places it firmly against the prevailing market sentiment. Current data shows that among 51 covering analysts, 33 maintain a “Buy” recommendation on Apple shares, while only two, including Jefferies, advocate selling. Despite being in the minority, this critical perspective has the potential to sow doubt among investors, especially with the company’s crucial quarterly results scheduled for release on October 30.

The upcoming Q4 earnings report is poised to serve as a critical test. It will offer clues as to whether the excitement surrounding Apple’s foldable ambitions is justified or if the company is once again overpromising. The investment community is eagerly awaiting any commentary from management regarding AI integration and, more importantly, concrete details about the foldable iPhone’s development. The nature of this guidance is likely to have a decisive impact on the stock’s future trajectory.

Ad

Apple Stock: Buy or Sell?! New Apple Analysis from February 7 delivers the answer:

The latest Apple figures speak for themselves: Urgent action needed for Apple investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Apple: Buy or sell? Read more here...

Tags: Apple
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Next Post
Unitedhealth Stock

Governance Crisis and Strategic Retreat Plague UnitedHealth

Lockheed Martin Stock

Lockheed Martin Stock Soars on Wave of Major Defense Contracts

Wolfspeed Stock

Wolfspeed Shares Stabilize Following Bankruptcy Exit Rally

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com